Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes
| Autor: | M M, Patnaik, E, Padron, R R, LaBorde, T L, Lasho, C M, Finke, C A, Hanson, J M, Hodnefield, R A, Knudson, R P, Ketterling, A, Al-kali, A, Pardanani, N A, Ali, R S, Komrokji, R S, Komroji, A, Tefferi |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Anemia Chronic myelomonocytic leukemia World Health Organization Gastroenterology Cohort Studies Young Adult Risk Factors Internal medicine Humans Medicine Lymphocyte Count Survival analysis Aged Aged 80 and over Univariate analysis Models Statistical Serine-Arginine Splicing Factors business.industry Nuclear Proteins Leukemia Myelomonocytic Chronic Hematology Middle Aged Ribonucleoprotein U2 Small Nuclear Phosphoproteins Prognosis Splicing Factor U2AF medicine.disease Survival Analysis Thrombocytopenia Confidence interval Surgery Repressor Proteins Leukemia Ribonucleoproteins Oncology Relative risk Spliceosomes Female RNA Splicing Factors business Follow-Up Studies Cohort study |
| Zdroj: | Leukemia. 27:1504-1510 |
| ISSN: | 1476-5551 0887-6924 |
| DOI: | 10.1038/leu.2013.88 |
| Popis: | We evaluated the prognostic relevance of several clinical and laboratory parameters in 226 Mayo Clinic patients with chronic myelomonocytic leukemia (CMML): 152 (67%) males and median age 71 years. At a median follow-up of 15 months, 166 (73%) deaths and 33 (14.5%) leukemic transformations were documented. In univariate analysis, significant risk factors for survival included anemia, thrombocytopenia, increased levels of white blood cells, absolute neutrophils, absolute monocyte count (AMC), absolute lymphocytes, peripheral blood and bone marrow blasts, and presence of circulating immature myeloid cells (IMCs). Spliceosome component (P=0.4) and ASXL1 mutations (P=0.37) had no impact survival. On multivariable analysis, increased AMC (>10 × 10(9)/l, relative risk (RR) 2.5, 95% confidence interval (CI) 1.7-3.8), presence of circulating IMC (RR 2.0, 95% CI 1.4-2.7), decreased hemoglobin ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|